| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.1 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.048 | 0.1 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.1 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.1 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.1 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.045 | 0.1 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |